From the databaseWhat the row says.
Every entry follows the same shape: what is happening, the mechanism, and the recommendation.
Scope
Supplement × Supplement
Last verified
June 4, 2026
SynergyModerate evidence
What is happening. Pterostilbene is the dimethylated analog of resveratrol with markedly higher oral bioavailability and a longer half-life. The two share overlapping mechanisms, including SIRT1 activation and antioxidant signaling, so combining them is mechanistically redundant rather than additive in distinct pathways.
Mechanism. Both compounds are stilbenes activating SIRT1 and Nrf2 pathways; pterostilbene's two methoxy groups increase lipophilicity, membrane permeability, and metabolic stability, yielding higher plasma exposure than resveratrol.
Recommendation. There is no clear advantage to stacking both; pterostilbene's superior bioavailability often makes it the practical choice. If both are used, keep total dosing modest and avoid assuming the effects simply add together.
Stack Score
How it moves the number.
Effect on the composite score
If both Pterostilbene and Resveratrol are in the same stack, this pair applies +2 to your Stack Score (per scored synergy row).
The full algorithm, the clamping rules, and four worked stacks are at /methodology/stack-score.
SourcesSources, by evidence tier.
Every claim on this page is cited. PMIDs link straight to PubMed.
Reference material
1- 1Kapetanovic IM, et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 2011.Needs sourceNo link